PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials.
Allison Booth, Shauna Hillman, Kristina Laumann, Ying-Qi Zhao, Michael LeBlanc, Kari Chansky, Sharmila Giri, Jennifer Dill, Judy Johnson, Kathryn Kelley, Linda Martin, Raymond U Osarogiagbon, Michael J Morris, Anne C Chiang, David E Kozono, Charles D Blanke, Evanthia Galanis, Jhanelle E Gray, Thomas E Stinchcombe, Raid Aljumaily, Daniel Morgensztern, Sumithra J Mandrekar
J Thorac Oncol 21(7) 103650
摘要
摘要
INTRODUCTION: Clinical trial designs marked by extensive data collection, restrictive eligibility, and lengthy protocols create inefficiencies, increase costs, and hinder accrual. These are further compounded by staffing shortages and operational burdens. By incorporating pragmatic features, including simplified eligibility criteria, streamlined protocol, and data collection, the PROSPECT-Lung trial, CTIU2317-A082304-S2402 Perioperative versus Adjuvant Systemic Therapy in Patients with Resectable NSCLC, paves the way forward as a model for enhancing clinical trial efficiency and feasibility, while maintaining scientific rigor. METHODS: PROSPECT-Lung (CTIU2317-A082304-S2402) is a pragmatic, phase III, open-label, randomized trial comparing 3-year real-world event-free survival and overall survival using approved perioperative and adjuvant immunotherapy-based treatment strategies in patients with resectable NSCLC. Protocol length and data collection elements were compared with Alliance A081801, Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO (ClinicalTrials.gov Identifier: NCT04267848), a phase III trial in the same disease setting, to quantify streamlining efforts. RESULTS: Relative to A081801, PROSPECT-Lung achieved major reductions in trial complexity. Protocol length decreased from 88 to 30 pages (65%), and data fields per patient were reduced from 2523 to 438 (82.6%), driven by streamlined summary versus cycle-by-cycle data collection. These efficiencies translate to estimated site workload reductions from 210 hours per patient in A081801 to 36.5 hours in PROSPECT-Lung. At full accrual, this equates to more than 190,000 hours saved in chart review, data entry, documentation, and quality control. CONCLUSION: By broadening eligibility and streamlining logistics, PROSPECT-Lung reduces burden for patients, investigators, and sites while preserving scientific integrity. This pragmatic approach, when appropriate and possible, provides a replicable model for future cancer trials, promoting efficiency, accessibility, and real-world relevance. GOV IDENTIFIER: NCT06632327 (CTIU2317-A082304-S2402).
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(6,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。